共 8 条
- [1] Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North AmericaPHARMACEUTICAL MEDICINE, 2019, 33 (06) : 511 - 518Kikuchi, MasashiAdachi, NoriakiMatsumaru, NaokiTsukamoto, Katsura
- [2] Unveiling Gaps and Demographic Influences in Alzheimer's Therapy: A Data-Centric Study of FDA-Approved Late-Phase Clinical TrialsNEUROLOGICAL SCIENCES, 2025,Kalokhe, Vaishnavi MilindSimran, SimranAhmad, AftabMusthafa, FathimaGangawane, Vishal SachinRaghuvanshi, Rajeev SinghSrivastava, Saurabh
- [3] Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trialsJournal of Pharmacokinetics and Pharmacodynamics, 2023, 50 : 45 - 62Kumar Kandadi MuralidharanKenneth G. KowalskiXiao TongSamantha Budd HaeberleinRajasimhan RajagovindanIvan Nestorov
- [4] Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trialsJournal of Pharmacokinetics and Pharmacodynamics, 2023, 50 : 145 - 145Kumar Kandadi MuralidharanKenneth G. KowalskiXiao TongSamantha Budd HaeberleinRajasimhan RajagovindanIvan Nestoro
- [5] Association between cognitive function, behavioral syndromes and two-year clinical outcome in Chinese subjects with late-onset Alzheimer's diseaseINTERNATIONAL PSYCHOGERIATRICS, 2006, 18 (03) : 517 - 526Lam, Linda C. W.Leung, TonyLiu, Victor W. C.Leung, Vivian P. Y.Chiu, Helen F. K.
- [6] Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trialsJOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (01) : 45 - 62Muralidharan, Kumar KandadiKowalski, Kenneth G. G.Tong, XiaoHaeberlein, Samantha BuddRajagovindan, RajasimhanNestorov, Ivan
- [7] Characterization of exposure-Clinical Dementia Rating-Sum of Boxes relationship in subjects with early Alzheimer's disease from the aducanumab Phase 3 trials (vol 50, pg 45, 2023)JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2023, 50 (02) : 145 - 145Muralidharan, Kumar KandadiKowalski, Kenneth G. G.Tong, XiaoHaeberlein, Samantha BuddRajagovindan, RajasimhanNestoro, Ivan
- [8] Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysisAGEING RESEARCH REVIEWS, 2023, 90Jeremic, DankoNavarro-Lopez, Juan D.Jimenez-Diaz, Lydia